Baird raised the firm’s price target on Nuvalent (NUVL) to $112 from $105 and keeps an Outperform rating on the shares. The firm updated its model following the release of pivotal data in Pretreated ROS1+NSCLC which confirmed its differentiated profile.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
- Nuvalent price target raised to $140 from $125 at Leerink
- Nuvalent price target raised to $130 from $110 at H.C. Wainwright
- Nuvalent’s Zidesamib: Promising Best-in-Class ROS1 TKI with Strong Efficacy and Safety Profile
- Nuvalent Announces Positive Data for Zidesamtinib Trial